Published in Blood Weekly, December 29th, 2005
Study 1: Patients with nonalcoholic steatohepatitis (NASH) and type 2 diabetes benefit from nateglinide.
"In the present study we administered nateglinide to NASH patients with type 2 diabetes who had failed to respond adequately to diet and exercise therapy, and we compared the resulting changes in insulin kinetics and improvements in blood glucose levels, as well as the concomitant changes in hepatic function, diagnostic liver images and liver histology, with the results from a non-treated control group," investigators in Japan report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.